Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/02683555211011794 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
2024 HRS perspective on advancing workflows for CIED remote monitoring.
Heart Rhythm O2
December 2024
Philips, San Diego, California.
Cardiac implantable electronic devices (CIEDs) generate substantial data, often stored in image or PDF formats. Remote monitoring, now an integral component of patient care, places considerable administrative burdens on clinicians and staff, in large part due to the challenge of integrating these data seamlessly into electronic health records. Since 2006, the Heart Rhythm Society, in collaboration with the CIED industry, has led an initiative to establish a unified standard nomenclature.
View Article and Find Full Text PDFInstagram Versus Reality: Who Are Actually Plastic Surgeons?
Plast Reconstr Surg Glob Open
January 2025
Division of Plastic and Reconstructive Surgery, Department of Surgery, Loyola University Stritch School of Medicine, Maywood, IL.
Background: Instagram has become one of the most powerful marketing tools available to plastic surgeons because patients have increasingly turned to online resources to find physicians. Within, we review the online presence of self-ascribed plastic surgeons in the United States to identify potential misinformation and dishonest advertising.
Methods: The Inflact database was queried for the search terms: "plastic surgeon/surgery," "plastic and reconstructive surgeon/surgery," "aesthetic surgeon/surgery," and "cosmetic surgeon/surgery.
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.
Med
January 2025
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France; University of Nebraska, Omaha, NE, USA. Electronic address:
Tumor-agnostic US Food and Drug Administration approvals are transforming oncology. They include larotrectinib/entrectinib/repotrectinib (NTRK fusions), selpercatinib (RET fusions), dabrafenib/trametinib (BRAF mutations), pembrolizumab/dostarlimab (microsatellite instability), pembrolizumab (high tumor mutational burden), and trastuzumab deruxtecan (HER2 3+ expression) (all solid cancers). Pemigatinib is approved for FGFR1-rearranged myeloid/lymphoid neoplasms.
View Article and Find Full Text PDFClinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an Fusion Through Use of EGFR Tyrosine Kinase Inhibitors.
JCO Precis Oncol
December 2024
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
J Thorac Oncol
November 2024
Department of Thoracic, Head, and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:
Article Synopsis
- - Drug resistance in EGFR-mutant non-small cell lung cancer (NSCLC) is complicated by mechanisms like pathway reactivation and fusion of receptor tyrosine kinases (RTKs), leading to challenges in treatment with tyrosine kinase inhibitors (TKIs).
- - A study involving multiple institutions analyzed 27 patients with RTK fusions identified through genetic testing, focusing on their response to dual TKI therapy, with results showing a 24% objective response rate and an 80% disease control rate overall.
- - The majority of patients had ALK or RET fusions, and those who received dual TKI treatment had a slightly lower response rate (21.4%) but no new side effects were reported, suggesting this approach
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!